Eagle Asset Management’s Vaxcyte PCVX Stock Holding History

Eagle Asset Management’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$18.8M	Sell	176,249 -106,102	-38%	-$9.56M	0.1%	196
2024 Q2	$21.7M	Sell	282,351 -56,449	-17%	-$3.84M	0.12%	169
2024 Q1	$22.6M	Sell	338,800 -15,323	-4%	-$1.06M	0.11%	174
2023 Q4	$22.2M	Sell	354,123 -885	-0.2%	-$46K	0.12%	177
2023 Q3	$18.1M	Sell	355,008 -6,078	-2%	-$300K	0.11%	188
2023 Q2	$18M	Buy	361,086 +133,393	+59%	+$6.32M	0.1%	195
2023 Q1	$8.53M	Buy	+227,693	New	+$9.66M	0.05%	268

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Eagle Asset Management's PCVX Position: Q3 2024 in Review

Eagle Asset Management reduced its Vaxcyte (PCVX) stake by 38% in Q3 2024, selling an estimated $9.56M and leaving 176,249 shares worth $18.8M. The position accounts for 0.1% of the portfolio, ranked #196.

Eagle Asset Management first reported a position in PCVX in Q1 2023 and has held it in 7 quarters since. The position peaked at $22.6M in Q1 2024. 328 funds tracked by Wall St. Rank hold PCVX as of Q3 2024.

Eagle Asset Management held 176,249 shares of Vaxcyte worth $18.8M as of Q3 2024.
Eagle Asset Management sold 106,102 Vaxcyte shares in Q3 2024, an estimated $9.56M.
Vaxcyte made up 0.1% of Eagle Asset Management's portfolio in Q3 2024, its #196 holding.
Eagle Asset Management first reported a position in Vaxcyte in Q1 2023 and has held it in 7 quarters since.
Eagle Asset Management's Vaxcyte position peaked at $22.6M in Q1 2024.
328 funds tracked by Wall St. Rank held Vaxcyte as of Q3 2024.

Based on Eagle Asset Management's 13F filing for Q3 2024, filed 12 Nov 2024.